{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:41:15Z","timestamp":1762875675018},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000735","name":"University of Cambridge","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000735","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000735","name":"University of Cambridge","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000735","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.atherosclerosis.2015.04.015","type":"journal-article","created":{"date-parts":[[2015,4,17]],"date-time":"2015-04-17T11:21:24Z","timestamp":1429269684000},"page":"439-445","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Efficacy and safety of P2Y12 inhibitors according to diabetes, age, gender, body mass index and body weight: Systematic review and meta-analyses of randomized clinical trials"],"prefix":"10.1016","volume":"240","author":[{"given":"Francesco","family":"Zaccardi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Pitocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Willeit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jari A.","family":"Laukkanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/ncpcardio0728","article-title":"Drug insight: aspirin resistance\u2013fact or fashion?","volume":"4","author":"Patrono","year":"2007","journal-title":"Nat. Clin. Pract. Cardiovasc. Med."},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib2","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/ehp097","article-title":"COX-1 sensitivity and TXA2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment","volume":"30","author":"Pulcinelli","year":"2009","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib3","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1111\/j.1538-7836.2007.02728.x","article-title":"Persistent platelet activation in patients with type 2 diabetes treated with low doses of aspirin","volume":"5","author":"Evangelista","year":"2007","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib4","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1136\/bmj.a1030","volume":"337","author":"Belch","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib5","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1001\/jama.2008.623","article-title":"Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes. A randomized controlled trial","volume":"300","author":"Ogawa","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b4531","article-title":"Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials","volume":"339","author":"De Berardis","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib7","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1161\/CIR.0b013e3181e3b133","volume":"121","author":"Pignone","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib8","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/eurheartj\/ehi684","article-title":"Aspirin and clopidogrel resistance: an emerging clinical entity","volume":"27","author":"Wang","year":"2006","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.beem.2008.12.001","article-title":"Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus","volume":"23","author":"Angiolillo","year":"2009","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib10","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jcin.2013.06.011","article-title":"Response variability to P2Y12 receptor inhibitors: expectations and reality","volume":"6","author":"Siller-Matula","year":"2013","journal-title":"JACC Cardiovasc. Interv."},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f5307","article-title":"Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison","volume":"347","author":"Gagne","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib12","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1160\/TH13-03-0250","article-title":"Why have studies of tailored anti-platelet therapy failed so far?","volume":"110","author":"Siller-Matula","year":"2013","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib13","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.2337\/dc09-1297","article-title":"Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes","volume":"32","author":"Calvin","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib15","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","article-title":"Assessing risk of bias in included studies","author":"Higgins","year":"2011"},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib16","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Interaction revisited: the difference between two estimates","volume":"326","author":"Altman","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib17","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib18","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMoa0901301","article-title":"Effect of clopidogrel added to aspirin in patients with atrial fibrillation","volume":"360","author":"Connolly","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib19","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A\u00a0randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","author":"CAPRIE Steering Committee","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib20","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0002-9149(02)02567-5","article-title":"Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus","volume":"90","author":"Bhatt","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack","volume":"369","author":"Wang","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib22","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib23","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.amjcard.2009.01.342","volume":"103","author":"Dasgupta","year":"2009","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib24","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.jacc.2009.05.074","article-title":"The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis","volume":"54","author":"Berger","year":"2009","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib25","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation","volume":"352","author":"Sabatine","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib26","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib27","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib28","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib29","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJMoa0909475","article-title":"Dose comparisons of clopidogrel and aspirin in acute coronary syndromes","volume":"363","author":"Mehta","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib30","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJMoa0805002","article-title":"Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke","volume":"359","author":"Sacco","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib31","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1056\/NEJMoa1204133","article-title":"Effects of clopidogrel added to aspirin in patients with recent lacunar stroke","volume":"367","author":"Benavente","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib32","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S0140-6736(89)92327-1","article-title":"The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke","volume":"1","author":"Gent","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005449.pub2","article-title":"Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus","volume":"11","author":"Valentine","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib34","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJM198908243210804","article-title":"A\u00a0randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group","volume":"321","author":"Hass","year":"1989","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib35","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa1308075","article-title":"Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes","volume":"369","author":"Montalescot","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib36","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib37","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib38","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1161\/CIRCULATIONAHA.108.791061","volume":"118","author":"Wiviott","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib39","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib40","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1093\/eurheartj\/ehq325","article-title":"Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"31","author":"James","year":"2010","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib41","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1161\/CIRCOUTCOMES.111.964395","article-title":"Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"5","author":"Husted","year":"2012","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib42","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib43","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib44","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib45","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1001\/2012.jama.10779","article-title":"Association of clopidogrel treatment with risk of mortality and cardiovascular events following myocardial infarction in patients with and without diabetes","volume":"308","author":"Andersson","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib46","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1093\/eurheartj\/ehi397","article-title":"Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases","volume":"26","author":"Jochmann","year":"2005","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib47","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s12471-011-0105-5","article-title":"Is platelet inhibition due to thienopyridines increased in elderly patients, in patients with previous stroke and patients with low body weight as a possible explanation of an increased bleeding risk?","volume":"19","author":"Breet","year":"2011","journal-title":"Neth. Heart J."},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib48","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.jacc.2010.02.031","article-title":"Impact of cytochrome P450 2C19 loss of function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement","volume":"55","author":"Hochholzer","year":"2010","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2015.04.015_bib49","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","volume":"34","author":"Ryd\u00e9n","year":"2013","journal-title":"Eur. Heart J."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915015002336?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915015002336?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,23]],"date-time":"2018-09-23T12:26:14Z","timestamp":1537705574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915015002336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0021915015002336"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.04.015","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of P2Y12 inhibitors according to diabetes, age, gender, body mass index and body weight: Systematic review and meta-analyses of randomized clinical trials","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}